Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA677: Autologous anti-CD19-transduced CD3+ cells for treating relapsed or refractory mantle cell lymphoma |
|
Medicine details |
|
Medicine name | Autologous anti-CD19-transduced CD3+ cells (brexucabtagene autoleucel [Tecartus®]) |
Formulation | Solution for infusion |
Reference number | 4795 |
Indication | Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor
|
Company | Gilead Sciences Ltd |
BNF chapter | Malignant disease & immunosuppression |
Assessment type | N/A |
Status | Excluded due to NICE appraisal |
Date of issue | 21/01/2021 |
NICE guidance |